Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Theravance - THRX -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (11)	4/20/2005 1:09:50 AM
From: hm	Read Replies (1) \| Respond to of 74

It's worth noting that Pat Humphrey, the EVP for discovery, came from GW at the time of the GW - SB merger. He is a top notch pharmacologist. He's credited with discovering sumatriptan (Imitrex)and Zofran, 2 Glaxo drugs with huge sales. I think he also had a hand in Lotronex, which made it market even if it's got a checkered history. If I remember correctly he started at Allen & Hanbury, an old British respiratory company that was bought out by Glaxo in the 80s. So the respiratory business shouldn't be too foreign to him. Anyway, Pat's got about as good a track record as there is in this business.